MRKR · Marker Therapeutics, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding our ability to continue as a going concern. Our condensed consolidated financial statements have been prepared on a going concern basis, which implies that we will continue to realize our assets and discharge our liabilities in the normal course of business. Our financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 | FY2002 | FY2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.95M | $3.55M | $6.59M | $3.31M | $3.51M | $0 | $500K | $213.19K | $205.99K | $183.06K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $8.81M | $11.8M | $13.47M | $10.42M | $11.97M | $27.79M | $18.88M | $12.76M | $7.95M | $5.25M | $3.8M | $1.71M | $189K | $697.63K | $1.06M | $203.73K | $290.05K | — | — | — | — | — | — | — | — | — | |
| $4.24M | $4.18M | $4.24M | $7.48M | $11.34M | $12.92M | $10.47M | $9.98M | $24.38M | $6.41M | $4.69M | $4.45M | $3.18M | $1.97M | $1.01M | $305.71K | $203.07K | — | — | — | — | — | — | — | — | — | |
| $3.03M | — | — | — | $2.79M | $2.15M | $485.64K | $105.12K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $13.05M | $16.44M | $17.71M | $17.89M | $23.3M | $40.72M | $29.35M | $22.74M | $148.38M | $11.66M | $8.49M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $5.12M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $3.32M | $5.47M | — | — | — | — | — | — | — | — | — | |
| -$9.5M | -$12.89M | -$11.12M | -$14.58M | -$19.79M | -$39.48M | -$28.89M | -$22.53M | -$148.17M | -$11.48M | -$8.49M | -$6.16M | -$3.37M | -$2.66M | — | -$3.32M | -$5.47M | — | — | — | — | — | — | — | — | — | |
| — | -363.45% | -168.69% | -440.37% | -563.28% | — | -5777.16% | -10567.28% | -71930.07% | -6271.05% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$11.27M | — | — | — | -$17M | -$37.33M | -$28.4M | -$22.42M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $549.14K | $594.21K | $437.01K | $539.16K | $248.06K | $5700 | $148.74K | $1.08M | $253.72K | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$12.18M | -$10.68M | -$14.04M | -$19.78M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$15.16K | $49.95K | $3675 | — | — | — | — | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$8.71M | -$12.16M | -$10.73M | -$8.24M | -$29.93M | -$41.88M | -$28.71M | -$21.43M | -$147.96M | -$10.98M | -$2.46M | -$34.07M | -$30.88M | -$5.53M | -$5.86M | -$2.03M | -$3.53M | -$17.35M | -$2.2M | -$3.89M | -$1.3M | -$985.6K | -$2.68M | -$5.78M | -$2.28M | -$671.99K | |
| — | -342.96% | -162.82% | -248.76% | -851.87% | — | -5741.21% | -10050.92% | -71826.32% | -5999.09% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | -$30.82M | -$5.53M | — | — | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | -$0.35 | -$0.79 | -$1.19 | -$0.94 | -$3.58 | -$5.47 | -$6.10 | — | — | -$11.60 | -$3.60 | -$93.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | -$0.35 | -$0.79 | -$1.19 | -$0.94 | -$3.58 | -$5.47 | -$6.10 | — | — | -$11.60 | -$7.20 | -$93.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 15.31M | 8.98M | 8.81M | 8.35M | 7.65M | 4.7M | 4.56M | 1.91M | 945.35K | 688.99K | 366.23K | 1.55M | 113.61K | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 15.31M | 8.98M | 8.81M | 8.35M | 7.65M | 4.7M | 4.56M | 1.91M | 945.35K | 742.1K | 366.23K | 1.55M | 113.61K | — | — | — | — | — | — | — | — | — | — | — | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2016–FY2018: $382.2K in buybacks.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Operating lease liabilities | 2023-03-31 | USD 7,489,000 | 10-Q filed 2023-05-15 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 268 similar-size Biotechnology companies (of 559 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cancer Prevention And Research Institute Of Texas Acute Myeloid Leukemia | $900,014 | $4,411,149 | — | — | — | — | — |
| National Institutes Of Health Small Business Innovation Research For Lymphoma Grant | $665,000 | $665,000 | — | — | — | — | — |
| Cprit Pancreatic Grant | $573,994 | — | — | — | — | — | — |
| National Institutes Of Health Small Business Innovation Research | $472,208 | $982,182 | $200,000 | — | — | — | — |
| National Institutes Of Health Small Business Innovation Research For Pancreatic Cancer | $425,670 | $7,177 | — | — | — | — | — |
| National Institutes Of Health National Cancer Institute Grant | $391,305 | $5,822 | — | — | — | — | — |
| Fda Grant | $118,478 | $519,750 | $400,000 | $100,000 | — | — | — |
| Cprit Grant | — | $200,000 | $2,700,000 | $3,400,000 | — | — | — |
| Grant | — | $6,591,080 | — | $3,513,544 | $1,241,710 | $466,785 | $213,194 |
| Service | — | — | — | $5,500,000 | — | — | — |